Design of Sphingosine Kinases Inhibitors: Challenges and Recent Developments

Author(s): Elisa Magli, Angela Corvino, Ferdinando Fiorino, Francesco Frecentese, Elisa Perissutti, Irene Saccone, Vincenzo Santagada, Giuseppe Caliendo*, Beatrice Severino.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 9 , 2019


Abstract:

Background: Sphingosine kinases (SphKs) catalyze the phosphorylation of sphingosine to form the bioactive sphingolipid metabolite sphingosine-1-phosphate (S1P). S1P is an important lipid mediator with a wide range of biological functions; it is also involved in a variety of diseases such as inflammatory diseases, Alzheimer’s disease and cancer.

Methods: This review reports the recent advancement in the research of SphKs inhibitors. Our purpose is also to provide a complete overview useful for underlining the features needed to select a specific pharmacological profile.

Discussion: Two distinct mammalian SphK isoforms have been identified, SphK1 and SphK2. These isoforms are encoded by different genes and exhibit distinct subcellular localizations, biochemical properties and functions. SphK1 and SphK2 inhibition can be useful in different pathological conditions.

Conclusion: SphK1 and SphK2 have many common features but different and even opposite biological functions. For this reason, several research groups are interested in understanding the therapeutic usefulness of a selective or non-selective inhibitor of SphKs. Moreover, a compensatory mechanism for the two isoforms has been demonstrated, thus leading to the development of dual inhibitors.

Keywords: Sphingosine-1-phosphate, Sphingosine Kinase 1, Sphingosine Kinase 2, design, dual inhibitors, selective inhibitors.

[1]
Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci 2011; 36(2): 97-107. [http://dx.doi.org/10.1016/j.tibs.2010.08.001]. [PMID: 20870412].
[2]
Birgbauer E, Chun J. New developments in the biological functions of lysophospholipids. Cell Mol Life Sci 2006; 63(23): 2695-701. [http://dx.doi.org/10.1007/s00018-006-6155-y]. [PMID: 16988788].
[3]
Gardell SE, Dubin AE, Chun J. Emerging medicinal roles for lysophospholipid signaling. Trends Mol Med 2006; 12(2): 65-75. [http://dx.doi.org/10.1016/j.molmed.2005.12.001]. [PMID: 16406843].
[4]
Sugiyama A, Yatomi Y, Ozaki Y, Hashimoto K. Sphingosine 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart. Cardiovasc Res 2000; 46(1): 119-25. [http://dx.doi.org/10.1016/S0008-6363(00)00013-4]. [PMID: 10727660].
[5]
Ohmori T, Yatomi Y, Osada M, et al. Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res 2003; 58(1): 170-7. [http://dx.doi.org/10.1016/S0008-6363(03)00260-8]. [PMID: 12667959].
[6]
Karliner JS. Lysophospholipids and the cardiovascular system. Biochim Biophys Acta 2002; 1582(1-3): 216-21. [http://dx.doi.org/10.1016/S1388-1981(02)00174-9]. [PMID: 12069831].
[7]
English D, Brindley DN, Spiegel S, Garcia JGN. Lipid mediators of angiogenesis and the signalling pathways they initiate. Biochim Biophys Acta 2002; 1582(1-3): 228-39. [http://dx.doi.org/10.1016/S1388-1981(02)00176-2]. [PMID: 12069833].
[8]
Garcia JGN, Liu F, Verin AD, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 2001; 108(5): 689-701. [http://dx.doi.org/10.1172/JCI12450]. [PMID: 11544274].
[9]
Spiegel S, Milstien S. Functions of the multifaceted family of sphingosine kinases and some close relatives. J Biol Chem 2007; 282(4): 2125-9. [http://dx.doi.org/10.1074/jbc.R600028200]. [PMID: 17135245].
[10]
Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 2005; 25(24): 11113-21. [http://dx.doi.org/10.1128/MCB.25.24.11113-11121.2005]. [PMID: 16314531].
[11]
Liu H, Sugiura M, Nava VE, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 2000; 275(26): 19513-20. [http://dx.doi.org/10.1074/jbc.M002759200]. [PMID: 10751414].
[12]
Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 2003; 554(1-2): 189-93. [http://dx.doi.org/10.1016/S0014-5793(03)01168-2]. [PMID: 14596938].
[13]
Neubauer HA, Pitson SM. Roles, regulation and inhibitors of sphingosine kinase 2. FEBS J 2013; 280(21): 5317-36. [http://dx.doi.org/10.1111/febs.12314]. [PMID: 23638983].
[14]
Maceyka M, Sankala H, Hait NC, et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 2005; 280(44): 37118-29. [http://dx.doi.org/10.1074/jbc.M502207200]. [PMID: 16118219].
[15]
Chipuk JE, McStay GP, Bharti A, et al. Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell 2012; 148(5): 988-1000. [http://dx.doi.org/10.1016/j.cell.2012.01.038]. [PMID: 22385963].
[16]
Hait NC, Allegood J, Maceyka M, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009; 325(5945): 1254-7. [http://dx.doi.org/10.1126/science.1176709]. [PMID: 19729656].
[17]
Wang J, Knapp S, Pyne NJ, Pyne S, Elkins JM. Crystal structure of sphingosine kinase 1 with PF-543. ACS Med Chem Lett 2014; 5(12): 1329-33. [http://dx.doi.org/10.1021/ml5004074]. [PMID: 25516793].
[18]
Wang Z, Min X, Xiao SH, et al. Molecular basis of sphingosine kinase 1 substrate recognition and catalysis. Structure 2013; 21(5): 798-809. [http://dx.doi.org/10.1016/j.str.2013.02.025]. [PMID: 23602659].
[19]
Adams DR, Pyne S, Pyne NJ. Sphingosine kinases: emerging structure-function insights. Trends Biochem Sci 2016; 41(5): 395-409. [http://dx.doi.org/10.1016/j.tibs.2016.02.007]. [PMID: 27021309].
[20]
Santos WL, Lynch KR. Drugging sphingosine kinases. ACS Chem Biol 2015; 10(1): 225-33. [http://dx.doi.org/10.1021/cb5008426]. [PMID: 25384187].
[21]
Pitman MR, Pitson SM. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets 2010; 10(4): 354-67. [http://dx.doi.org/10.2174/156800910791208599]. [PMID: 20370685].
[22]
(a)Sanllehí P, Abad JL, Bujons J, Casas J, Delgado A. Studies on the inhibition of sphingosine-1-phosphate lyase by stabilized reaction intermediates and stereodefined azido phosphates. Eur J Med Chem 2016; 123: 905-15. [http://dx.doi.org/10.1016/j.ejmech.2016.08.008].[PMID: 27543882]; (b)Dinges J, Harris CM, Wallace GA, et al. Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors. Bioorg Med Chem Lett 2016; 26(9): 2297-302. [http://dx.doi.org/10.1016/j.bmcl.2016.03.043] [PMID: 27020302]
[23]
Gao P, Peterson YK, Smith RA, Smith CD. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS One 2012; 7(9): e44543. [http://dx.doi.org/10.1371/journal.pone.0044543]. [PMID: 22970244].
[24]
(a)Bakali HM, Herman MD, Johnson KA, et al. Crystal structure of YegS, a homologue to the mammalian diacylglycerol kinases, reveals a novel regulatory metal binding site. J Biol Chem 2007; 282(27): 19644-52. [http://dx.doi.org/10.1074/jbc.M604852200]. [PMID: 17351295]; (b)Bakali MA, Nordlund P, Hallberg BM. Expression, purification, crystallization and preliminary diffraction studies of the mammalian DAG kinase homologue YegS from Escherichia coli. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006; 62(Pt 3): 295-7. [http://dx.doi.org/10.1107/S1744309106004799]. [PMID: 16511327].
[25]
Dickson MA, Carvajal RD, Merrill AH Jr, Gonen M, Cane LM, Schwartz GK. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res 2011; 17(8): 2484-92. [http://dx.doi.org/10.1158/1078-0432.CCR-10-2323]. [PMID: 21257722].
[26]
Venkataraman K, Thangada S, Michaud J, et al. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J 2006; 397(3): 461-71. [http://dx.doi.org/10.1042/BJ20060251]. [PMID: 16623665].
[27]
Pitson SM, D’andrea RJ, Vandeleur L, et al. Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes. Biochem J 2000; 350(Pt 2): 429-41. [http://dx.doi.org/10.1042/bj3500429]. [PMID: 10947957].
[28]
Yokota S, Taniguchi Y, Kihara A, Mitsutake S, Igarashi Y. Asp177 in C4 domain of mouse sphingosine kinase 1a is important for the sphingosine recognition. FEBS Lett 2004; 578(1-2): 106-10. [http://dx.doi.org/10.1016/j.febslet.2004.10.081]. [PMID: 15581625].
[29]
Pitson SM, Moretti PA, Zebol JR, et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J 2003; 22(20): 5491-500. [http://dx.doi.org/10.1093/emboj/cdg540]. [PMID: 14532121].
[30]
Stahelin RV, Hwang JH, Kim JH, et al. The mechanism of membrane targeting of human sphingosine kinase 1. J Biol Chem 2005; 280(52): 43030-8. [http://dx.doi.org/10.1074/jbc.M507574200]. [PMID: 16243846].
[31]
Yatomi Y, Ruan F, Megidish T, Toyokuni T, Hakomori S, Igarashi Y N. N-dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. Biochemistry 1996; 35(2): 626-33. [http://dx.doi.org/10.1021/bi9515533]. [PMID: 8555236].
[32]
Edsall LC, Van Brocklyn JR, Cuvillier O, Kleuser B, Spiegel SN. N-Dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry 1998; 37(37): 12892-8. [http://dx.doi.org/10.1021/bi980744d]. [PMID: 9737868].
[33]
Endo K, Igarashi Y, Nisar M, Zhou QH, Hakomori S. Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer Res 1991; 51(6): 1613-8. [PMID: 1998952].
[34]
Sweeney EA, Sakakura C, Shirahama T, et al. Sphingosine and its methylated derivative N,N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int J Cancer 1996; 66(3): 358-66. [http://dx.doi.org/10.1002/(SICI)1097-0215(19960503)66:3<358:AID-IJC16>3.0.CO;2-7]. [PMID: 8621258].
[35]
Olivera A, Kohama T, Edsall L, et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 1999; 147(3): 545-58. [http://dx.doi.org/10.1083/jcb.147.3.545]. [PMID: 10545499].
[36]
French KJ, Schrecengost RS, Lee BD, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63(18): 5962-9. [PMID: 14522923].
[37]
Lim KG, Tonelli F, Li Z, et al. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem 2011; 286(21): 18633-40. [http://dx.doi.org/10.1074/jbc.M111.220756]. [PMID: 21464128].
[38]
Loveridge C, Tonelli F, Leclercq T, et al. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem 2010; 285(50): 38841-52. [http://dx.doi.org/10.1074/jbc.M110.127993]. [PMID: 20926375].
[39]
Tonelli F, Lim KG, Loveridge C, et al. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal 2010; 22(10): 1536-42. [http://dx.doi.org/10.1016/j.cellsig.2010.05.022]. [PMID: 20570726].
[40]
Cingolani F, Casasampere M, Sanllehí P, Casas J, Bujons J, Fabrias G. Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II. J Lipid Res 2014; 55(8): 1711-20. [http://dx.doi.org/10.1194/jlr.M049759]. [PMID: 24875537].
[41]
Noack J, Choi J, Richter K, Kopp-Schneider A, Régnier-Vigouroux A. A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy. Cell Death Dis 2014; 5: e1425. [http://dx.doi.org/10.1038/cddis.2014.384]. [PMID: 25255218].
[42]
Aurelio L, Scullino CV, Pitman MR, et al. From sphingosine kinase to dihydroceramide desaturase: a structure-activity relationship (SAR) study of the enzyme inhibitory and anticancer activity of 4-((4-(4-chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II). J Med Chem 2016; 59(3): 965-84. [http://dx.doi.org/10.1021/acs.jmedchem.5b01439]. [PMID: 26780304].
[43]
Antoon JW, White MD, Burow ME, Beckman BS. Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance. Oncol Rep 2012; 27(6): 1779-86. [PMID: 22469881].
[44]
Martin JL, de Silva HC, Lin MZ, Scott CD, Baxter RC. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol Cancer Ther 2014; 13(2): 316-28. [http://dx.doi.org/10.1158/1535-7163.MCT-13-0367]. [PMID: 24337110].
[45]
Yang L, Weng W, Sun ZX, Fu XJ, Ma J, Zhuang WF. SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo. Biochem Biophys Res Commun 2015; 460(4): 903-8. [http://dx.doi.org/10.1016/j.bbrc.2015.03.114]. [PMID: 25824043].
[46]
Song L, Xiong H, Li J, et al. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer. Clin Cancer Res 2011; 17(7): 1839-49. [http://dx.doi.org/10.1158/1078-0432.CCR-10-0720]. [PMID: 21325072].
[47]
Huang LS, Berdyshev E, Mathew B, et al. Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis. FASEB J 2013; 27(4): 1749-60. [http://dx.doi.org/10.1096/fj.12-219634]. [PMID: 23315259].
[48]
Finley A, Chen Z, Esposito E, Cuzzocrea S, Sabbadini R, Salvemini D. Sphingosine 1-phosphate mediates hyperalgesia via a neutrophil-dependent mechanism. PLoS One 2013; 8(1): e55255. [http://dx.doi.org/10.1371/journal.pone.0055255]. [PMID: 23372844].
[49]
Mercado N, Kizawa Y, Ueda K, et al. Activation of transcription factor Nrf2 signalling by the sphingosine kinase inhibitor SKI-II is mediated by the formation of Keap1 dimers. PLoS One 2014; 9(2): e88168. [http://dx.doi.org/10.1371/journal.pone.0088168]. [PMID: 24505412].
[50]
Barnes PJ. Mechanisms of development of multimorbidity in the elderly. Eur Respir J 2015; 45(3): 790-806. [http://dx.doi.org/10.1183/09031936.00229714]. [PMID: 25614163].
[51]
Hengst JA, Wang X, Sk UH, Sharma AK, Amin S, Yun JK. Development of a sphingosine kinase 1 specific small-molecule inhibitor. Bioorg Med Chem Lett 2010; 20(24): 7498-502. [http://dx.doi.org/10.1016/j.bmcl.2010.10.005]. [PMID: 21050755].
[52]
Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP. Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res 2012; 25(2): 259-74. [http://dx.doi.org/10.1111/j.1755-148X.2012.00970.x]. [PMID: 22236408].
[53]
Young MM, Takahashi Y, Khan O, et al. Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis. J Biol Chem 2012; 287(15): 12455-68. [http://dx.doi.org/10.1074/jbc.M111.309104]. [PMID: 22362782].
[54]
Sharma AK, Sk UH, Gimbor MA, et al. Synthesis and bioactivity of sphingosine kinase inhibitors and their novel aspirinyl conjugated analogs. Eur J Med Chem 2010; 45(9): 4149-56. [http://dx.doi.org/10.1016/j.ejmech.2010.06.005]. [PMID: 20598402].
[55]
French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006; 318(2): 596-603. [http://dx.doi.org/10.1124/jpet.106.101345]. [PMID: 16632640].
[56]
Pitman MR, Powell JA, Coolen C, et al. A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties. Oncotarget 2015; 6(9): 7065-83. [http://dx.doi.org/10.18632/oncotarget.3178]. [PMID: 25788259].
[57]
Sharma AK. Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247). Expert Opin Ther Pat 2011; 21(5): 807-12. [http://dx.doi.org/10.1517/13543776.2011.573787]. [PMID: 21457086].
[58]
Paugh SW, Paugh BS, Rahmani M, et al. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 2008; 112(4): 1382-91. [http://dx.doi.org/10.1182/blood-2008-02-138958]. [PMID: 18511810].
[59]
Nagahashi M, Ramachandran S, Kim EY, et al. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res 2012; 72(3): 726-35. [http://dx.doi.org/10.1158/0008-5472.CAN-11-2167]. [PMID: 22298596].
[60]
Hazar-Rethinam M, de Long LM, Gannon OM, et al. A novel E2F/sphingosine kinase 1 axis regulates anthracycline response in squamous cell carcinoma. Clin Cancer Res 2015; 21(2): 417-27. [http://dx.doi.org/10.1158/1078-0432.CCR-14-1962]. [PMID: 25411162].
[61]
Price MM, Oskeritzian CA, Falanga YT, et al. A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. J Allergy Clin Immunol 2013; 131(2): 501-11.e1. [http://dx.doi.org/10.1016/j.jaci.2012.07.014]. [PMID: 22939756].
[62]
Schnute ME, McReynolds MD, Kasten T, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J 2012; 444(1): 79-88. [http://dx.doi.org/10.1042/BJ20111929]. [PMID: 22397330].
[63]
Byun HS, Pyne S, Macritchie N, Pyne NJ, Bittman R. Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells. MedChemComm 2013; 4(10): 4. [http://dx.doi.org/10.1039/c3md00201b]. [PMID: 24396570].
[64]
Lv M, Zhang D, Dai D, Zhang W, Zhang L. Sphingosine kinase 1/sphingosine-1-phosphate regulates the expression of interleukin-17A in activated microglia in cerebral ischemia/reperfusion. Inflamm Res 2016; 65(7): 551-62. [http://dx.doi.org/10.1007/s00011-016-0939-9]. [PMID: 27002656].
[65]
Zhang Y, Berka V, Song A, et al. Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. J Clin Invest 2014; 124(6): 2750-61. [http://dx.doi.org/10.1172/JCI74604]. [PMID: 24837436].
[66]
MacRitchie N, Volpert G, Al Washih M, et al. Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension. Cell Signal 2016; 28(8): 946-55. [http://dx.doi.org/10.1016/j.cellsig.2016.03.014]. [PMID: 27063355].
[67]
Ju T, Gao D, Fang ZY. Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543. Biochem Biophys Res Commun 2016; 470(3): 728-34. [http://dx.doi.org/10.1016/j.bbrc.2016.01.053]. [PMID: 26775841].
[68]
Dick TE, Hengst JA, Fox TE, et al. The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines. J Pharmacol Exp Ther 2015; 352(3): 494-508. [http://dx.doi.org/10.1124/jpet.114.219659]. [PMID: 25563902].
[69]
Gustin DJ, Li Y, Brown ML, et al. Structure guided design of a series of sphingosine kinase (SphK) inhibitors. Bioorg Med Chem Lett 2013; 23(16): 4608-16. [http://dx.doi.org/10.1016/j.bmcl.2013.06.030]. [PMID: 23845219].
[70]
Rex K, Jeffries S, Brown ML, et al. Sphingosine kinase activity is not required for tumor cell viability. PLoS One 2013; 8(7): e68328. [http://dx.doi.org/10.1371/journal.pone.0068328]. [PMID: 23861887].
[71]
Mathews TP, Kennedy AJ, Kharel Y, et al. Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors. J Med Chem 2010; 53(7): 2766-78. [http://dx.doi.org/10.1021/jm901860h]. [PMID: 20205392].
[72]
Foss FW Jr, Mathews TP, Kharel Y, et al. Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs. Bioorg Med Chem 2009; 17(16): 6123-36. [http://dx.doi.org/10.1016/j.bmc.2009.04.015]. [PMID: 19632123].
[73]
Xiang Y, Hirth B, Kane JL Jr, et al. Discovery of novel sphingosine kinase-1 inhibitors. Part 2. Bioorg Med Chem Lett 2010; 20(15): 4550-4. [http://dx.doi.org/10.1016/j.bmcl.2010.06.019]. [PMID: 20598880].
[74]
Patwardhan NN, Morris EA, Kharel Y, et al. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors. J Med Chem 2015; 58(4): 1879-99. [http://dx.doi.org/10.1021/jm501760d]. [PMID: 25643074].
[75]
Childress ES, Kharel Y, Brown AM, Bevan DR, Lynch KR, Santos WL. Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity. J Med Chem 2017; 60(9): 3933-57. [http://dx.doi.org/10.1021/acs.jmedchem.7b00233]. [PMID: 28406646].
[76]
Corvino A, Rosa R, Incisivo GM, et al. Development of 1,2,3-triazole-based sphingosine kinase inhibitors and their evaluation as antiproliferative agents. Int J Mol Sci 2017; 18(11): 2332. [http://dx.doi.org/10.3390/ijms18112332]. [PMID: 29113071].
[77]
Escudero-Casao M, Cardona A, Beltrán-Debón R, Díaz Y, Matheu MI, Castillón S. Fluorinated triazole-containing sphingosine analogues. Syntheses and in vitro evaluation as SPHK inhibitors. Org Biomol Chem 2018; 16(39): 7230-5. [http://dx.doi.org/10.1039/C8OB01867G]. [PMID: 30255187].
[78]
French KJ, Zhuang Y, Maines LW, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010; 333(1): 129-39. [http://dx.doi.org/10.1124/jpet.109.163444]. [PMID: 20061445].
[79]
Gao P, Smith CD. Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration. Mol Cancer Res 2011; 9(11): 1509-19. [http://dx.doi.org/10.1158/1541-7786.MCR-11-0336]. [PMID: 21896638].
[80]
Antoon JW, White MD, Slaughter EM, et al. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 2011; 11(7): 678-89. [http://dx.doi.org/10.4161/cbt.11.7.14903]. [PMID: 21307639].
[81]
Antoon JW, White MD, Driver JL, Burow ME, Beckman BS. Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. Exp Biol Med (Maywood) 2012; 237(7): 832-44. [http://dx.doi.org/10.1258/ebm.2012.012028]. [PMID: 22859737].
[82]
Beljanski V, Knaak C, Zhuang Y, Smith CD. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs 2011; 29(6): 1132-42. [http://dx.doi.org/10.1007/s10637-010-9452-0]. [PMID: 20473784].
[83]
Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther 2011; 11(5): 524-34. [http://dx.doi.org/10.4161/cbt.11.5.14677]. [PMID: 21258214].
[84]
Chumanevich AA, Poudyal D, Cui X, et al. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis 2010; 31(10): 1787-93. [http://dx.doi.org/10.1093/carcin/bgq158]. [PMID: 20688834].
[85]
Xun C, Chen M-B, Qi L, et al. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo. J Exp Clin Cancer Res 2015; 34: 94. [http://dx.doi.org/10.1186/s13046-015-0205-y]. [PMID: 26337959].
[86]
Fitzpatrick LR, Green C, Maines LW, Smith CD. Experimental osteoarthritis in rats is attenuated by ABC294640, a selective inhibitor of sphingosine kinase-2. Pharmacology 2011; 87(3-4): 135-43. [http://dx.doi.org/10.1159/000323911]. [PMID: 21346391].
[87]
Fitzpatrick LR, Green C, Frauenhoffer EE, et al. Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase. Inflammopharmacology 2011; 19(2): 75-87. [http://dx.doi.org/10.1007/s10787-010-0060-6]. [PMID: 20936538].
[88]
Maines LW, French KJ, Wolpert EB, Antonetti DA, Smith CD. Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases. Invest Ophthalmol Vis Sci 2006; 47(11): 5022-31. [http://dx.doi.org/10.1167/iovs.05-1236]. [PMID: 17065523].
[89]
Maines LW, Fitzpatrick LR, Green CL, Zhuang Y, Smith CD. Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn’s disease. Inflammopharmacology 2010; 18(2): 73-85. [http://dx.doi.org/10.1007/s10787-010-0032-x]. [PMID: 20151210].
[90]
Maines LW, Fitzpatrick LR, French KJ, et al. Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci 2008; 53(4): 997-1012. [http://dx.doi.org/10.1007/s10620-007-0133-6]. [PMID: 18058233].
[91]
Moruno-Manchon JF, Uzor N-E, Blasco-Conesa MP, et al. Inhibiting sphingosine kinase 2 mitigates mutant Huntingtin-induced neurodegeneration in neuron models of Huntington disease. Hum Mol Genet 2017; 26(7): 1305-17. [http://dx.doi.org/10.1093/hmg/ddx046]. [PMID: 28175299].
[92]
Antoon JW, White MD, Meacham WD, et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 2010; 151(11): 5124-35. [http://dx.doi.org/10.1210/en.2010-0420]. [PMID: 20861237].
[93]
Dai L, Bai A, Smith CD, Rodriguez PC, Yu F, Qin Z. ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus-Infected Cell Autophagic Death and Represses Tumor Growth. Mol Cancer Ther 2017; 16(12): 2724-34. [http://dx.doi.org/10.1158/1535-7163.MCT-17-0485]. [PMID: 28939554].
[94]
Leili H, Nasser S, Nadereh R, Siavoush D, Pouran K. Sphingosine kinase-2 inhibitor ABC294640 enhances doxorubicin-induced apoptosis of NSCLC cells via altering survivin expression. Drug Res (Stuttg) 2018; 68(1): 45-53. [http://dx.doi.org/10.1055/s-0043-117181]. [PMID: 28950390].
[95]
Dai L, Smith CD, Foroozesh M, Miele L, Qin Z. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo. Int J Cancer 2018; 142(10): 2153-62. [http://dx.doi.org/10.1002/ijc.31234]. [PMID: 29277894].
[96]
Liu K, Guo TL, Hait NC, et al. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One 2013; 8(2): e56471. [http://dx.doi.org/10.1371/journal.pone.0056471]. [PMID: 23437140].
[97]
Shi Y, Qiao J, Mu B, Zuo B, Yuan J. 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) ameliorated dexamethasone induced hepatic gluconeogenesis through activation of Akt/FoxO1 pathway. Biochem Biophys Res Commun 2017; 493(1): 286-90. [http://dx.doi.org/10.1016/j.bbrc.2017.09.029]. [PMID: 28911865].
[98]
Kharel Y, Raje M, Gao M, et al. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate. Biochem J 2012; 447(1): 149-57. [http://dx.doi.org/10.1042/BJ20120609]. [PMID: 22747486].
[99]
Kharel Y, Morris EA, Congdon MD, et al. Sphingosine kinase 2 inhibiton and blood sphingosine 1-phosphate levels. J Pharmacol Exp Ther 2015; 355(1): 23-31. [http://dx.doi.org/10.1124/jpet.115.225862]. [PMID: 26243740].
[100]
Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9(11): 883-97. [http://dx.doi.org/10.1038/nrd3248]. [PMID: 21031003].
[101]
Gault CR, Obeid LM. Still benched on its way to the bedside: sphingosine kinase 1 as an emerging target in cancer chemotherapy. Crit Rev Biochem Mol Biol 2011; 46(4): 342-51. [http://dx.doi.org/10.3109/10409238.2011.597737]. [PMID: 21787121].
[102]
Lim KG, Sun C, Bittman R, Pyne NJ, Pyne S. (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell Signal 2011; 23(10): 1590-5. [http://dx.doi.org/10.1016/j.cellsig.2011.05.010]. [PMID: 21620961].
[103]
Evangelisti C, Evangelisti C, Teti G, et al. Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. Oncotarget 2014; 5(17): 7886-901. [http://dx.doi.org/10.18632/oncotarget.2318]. [PMID: 25226616].
[104]
Ohotski J, Rosen H, Bittman R, Pyne S, Pyne NJ. Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: The role of sphingosine 1-phosphate receptor-4. Cell Signal 2014; 26(5): 1040-7. [http://dx.doi.org/10.1016/j.cellsig.2014.01.023]. [PMID: 24486401].
[105]
Camp SM, Chiang ET, Sun C, et al. Pulmonary endothelial cell barrier enhancement by novel FTY720 an- alogs: methoxy-FTY720, fluoro-FTY720, and beta-glucuronide-FTY720. Chem Phys Lipids 2016; 194: 85-93. [http://dx.doi.org/10.1016/j.chemphyslip.2015.10.004]. [PMID: 26496151].
[106]
Berdyshev EV, Gorshkova I, Skobeleva A, et al. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells. J Biol Chem 2009; 284(9): 5467-77. [http://dx.doi.org/10.1074/jbc.M805186200]. [PMID: 19119142].
[107]
Tonelli F, Alossaimi M, Natarajan V, et al. The roles of sphingosine kinase 1 and 2 in regulating the metabolome and survival of prostate cancer cells. Biomolecules 2013; 3(2): 316-33. [http://dx.doi.org/10.3390/biom3020316]. [PMID: 24970170].
[108]
Kim JW, Kim YW, Inagaki Y, et al. Synthesis and evaluation of sphingoid analogs as inhibitors of sphingosine kinases. Bioorg Med Chem 2005; 13(10): 3475-85. [http://dx.doi.org/10.1016/j.bmc.2005.02.053]. [PMID: 15848761].
[109]
Hara-Yokoyama M, Terasawa K, Ichinose S, et al. Sphingosine kinase 2 inhibitor SG-12 induces apoptosis via phosphorylation by sphingosine kinase 2. Bioorg Med Chem Lett 2013; 23(7): 2220-4. [http://dx.doi.org/10.1016/j.bmcl.2013.01.083]. [PMID: 23434415].
[110]
Zhao Y, Ling Z, Hao Y, et al. MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine kinase 1 and its downstream signaling in head and neck squamous cell carcinoma. Oncotarget 2017; 8(15): 25005-20. [http://dx.doi.org/10.18632/oncotarget.15334]. [PMID: 28212569].
[111]
Lu PH, Chen MB, Liu YY, et al. Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells. Oncotarget 2017; 8(14): 22800-10. [http://dx.doi.org/10.18632/oncotarget.15205]. [PMID: 28206952].
[112]
Zhou Y, Han Y, Zhang Z, et al. MicroRNA-124 upregulation inhibits proliferation and invasion of osteosarcoma cells by targeting sphingosine kinase 1. Hum Cell 2017; 30(1): 30-40. [http://dx.doi.org/10.1007/s13577-016-0148-4]. [PMID: 27743351].
[113]
Lee MS, Lee SO, Kim KR, Lee HJ. Sphingosine kinase 1 involves the inhibitory action of HIF-1 by chlorogenic acid in hypoxic DU145 cells. Int J Mol Sci 2017; 18(2): 325-13.
[114]
Neiband MS, Mani-Varnosfaderani A, Benvidi A. Classification of sphingosine kinase inhibitors using counter propagation artificial neural networks: A systematic route for designing selective SphK inhibitors. SAR QSAR Environ Res 2017; 28(2): 91-109. [http://dx.doi.org/10.1080/1062936X.2017.1280535]. [PMID: 28121178].
[115]
Vettorazzi M, Angelina E, Lima S, et al. An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors. Eur J Med Chem 2017; 139: 461-81. [http://dx.doi.org/10.1016/j.ejmech.2017.08.017]. [PMID: 28822281].


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 9
Year: 2019
Page: [956 - 968]
Pages: 13
DOI: 10.2174/1381612825666190404115424
Price: $58

Article Metrics

PDF: 33
HTML: 4
EPUB: 1
PRC: 1

Special-new-year-discount